LifeMD (NASDAQ:LFMD) Price Target Lowered to $7.00 at KeyCorp

LifeMD (NASDAQ:LFMDGet Free Report) had its price target decreased by equities research analysts at KeyCorp from $10.00 to $7.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. KeyCorp’s price objective would suggest a potential upside of 37.25% from the company’s current price.

Several other research analysts also recently commented on LFMD. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of LifeMD in a research note on Monday, November 11th. Lake Street Capital began coverage on shares of LifeMD in a research report on Tuesday, December 10th. They set a “buy” rating and a $12.00 target price on the stock. Mizuho assumed coverage on LifeMD in a report on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 price target for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 price objective on shares of LifeMD in a research note on Friday, September 20th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.14.

Check Out Our Latest Research Report on LFMD

LifeMD Stock Performance

LFMD stock opened at $5.10 on Wednesday. LifeMD has a twelve month low of $3.99 and a twelve month high of $12.88. The firm has a market cap of $220.89 million, a price-to-earnings ratio of -7.97 and a beta of 1.49. The business’s fifty day simple moving average is $5.59 and its two-hundred day simple moving average is $5.55. The company has a quick ratio of 0.78, a current ratio of 0.83 and a debt-to-equity ratio of 10.83.

Insider Activity at LifeMD

In other LifeMD news, CEO Justin Schreiber sold 25,000 shares of LifeMD stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $5.19, for a total value of $129,750.00. Following the transaction, the chief executive officer now owns 2,703,715 shares in the company, valued at $14,032,280.85. The trade was a 0.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 15.97% of the stock is currently owned by corporate insiders.

Institutional Trading of LifeMD

Several hedge funds have recently modified their holdings of LFMD. Quest Partners LLC bought a new position in shares of LifeMD during the 2nd quarter worth approximately $31,000. nVerses Capital LLC acquired a new position in shares of LifeMD during the third quarter worth $46,000. Intech Investment Management LLC purchased a new stake in shares of LifeMD during the 3rd quarter valued at $54,000. CWM LLC acquired a new stake in shares of LifeMD in the 3rd quarter worth $59,000. Finally, SG Americas Securities LLC purchased a new position in LifeMD during the 3rd quarter worth $70,000. 35.52% of the stock is owned by hedge funds and other institutional investors.

About LifeMD

(Get Free Report)

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.

Further Reading

Analyst Recommendations for LifeMD (NASDAQ:LFMD)

Receive News & Ratings for LifeMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeMD and related companies with MarketBeat.com's FREE daily email newsletter.